Early warnings for cancer drug trials.

When a drug trial is in trouble, companies rarely say so right away. But clues show up first. Tremor watches for them and gives every trial a worry score from 0 to 100.

cancer trials watched: 1,669
public companies: 196
last checked: on Nov 9, 2026

Biggest worries right now

Trials with the most warning signs. A high score is not a prediction.

85Tremor
NVSStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
The trial was stopped early, so it goes straight to red + 1 more
35Calm
CLLSPhase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Changed the trial's main goal + 1 more
34Calm
ARTVAB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Announced layoffs or restructuring + 2 more
22Calm
VSTMA Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
A key executive is leaving + 1 more
20Calm
BMYA Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
Main results were due Sep 2025, none posted yet + 2 more
20Calm
BMYAn Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Main results were due Oct 2025, none posted yet + 2 more
20Calm
BMYA Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Main results were due Aug 2025, none posted yet + 2 more
18Calm
IONSGOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Main results were due Apr 2024, none posted yet + 1 more

Latest changes

Show minor changes too

CLLSPhase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)35Calm
Pushed back the final finish date by about 17 months: Jun 30, 2026 → Dec 2027.
Cellectis, a company that makes cell-based cancer treatments, pushed back the expected finish date of its UCART22 leukemia study from June 30, 2026 to December 2027, about 17 months later. Investors often watch for delays like this because they can hint that a study is running slower than planned, which may raise questions about when results will arrive. A date change like this also has ordinary explanations, such as scheduling adjustments or a steady pace of follow-up, and the company hasn't said why it moved, so on its own it doesn't prove anything about how the study is going.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 9, 2026
CLLSPhase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)35Calm
Changed the trial's main goal (what counts as success).
Cellectis changed what the UCART22 leukemia trial counts as success, adding a goal about how many patients get a complete response (the leukemia going into remission) on top of the earlier focus on safety and side effects. Investors often watch changes like this because a trial that adds or shifts its main goal can signal that the company is rethinking what it expects to show, which can point to worry about the original plan. The change can also have ordinary reasons, such as adding a measure that regulators or researchers asked for, so on its own it doesn't prove anything about how the drug is doing.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 9, 2026
NVSStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer85Tremor
The trial was stopped early.
Novartis has stopped a late-stage study of a lung cancer drug early, after it had been running and planned for 95 patients. The company hasn't said why it stopped. Investors watch a change like this because an early stop in a late-stage trial can sometimes signal that the drug is not working as hoped, or that it may be causing problems, and that could affect the company's future sales. The same kind of stop can also happen for ordinary reasons, such as slow patient enrollment, shifts in company priorities, or results that are not clear enough to justify continuing, so this change alone doesn't prove the drug has failed.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
RIGLStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)10Calm
Pushed back the final finish date by about 24 months: Dec 2026 → Dec 2028.
The company moved the expected finish date for its study of R289 in people with lower-risk myelodysplastic syndromes (a group of blood disorders) from December 2026 to December 2028, a delay of about 24 months. Investors watch changes like this because a longer timeline can hint that patients are joining more slowly than planned or that the study design is being reworked, which could mean results come later and cost more. A date moving can also have ordinary causes, such as scheduling adjustments or paperwork, and the company hasn't said why it changed, so this alone doesn't show whether the study is in trouble.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
RIGLStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)10Calm
Pushed back the main results date by about 16 months: Aug 2026 → Dec 2027.
A drug study from Rigel Pharmaceuticals has pushed back the date when its main results are expected, from August 2026 to December 2027, a delay of about 16 months. Investors often watch changes like this because a delay can sometimes mean the study is taking longer than planned, perhaps due to trouble finding or keeping patients, or because the company is adjusting how it will judge the drug, and either could point to a weaker outlook than expected. But schedules shift for many ordinary reasons, such as slower patient sign-ups or simple planning updates, and the company hasn't said why this one moved, so a later date on its own doesn't prove anything about the drug or the company.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
JAZZA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC12Calm
Pushed back the final finish date by about 18 months: Apr 30, 2028 → Nov 4, 2029.
Spotted on Nov 6, 2026
JAZZA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC12Calm
Pushed back the main results date by about 18 months: Jan 31, 2028 → Aug 4, 2029.
Jazz Pharmaceuticals pushed back the date when the main results from its lung cancer study are expected, from 2028-01-31 to 2029-08-04, about 18 months later. The study is a mid-stage test (called Phase 2) that is still enrolling patients, meaning it is still signing up people to take part, with 50 planned. Investors watch a delay like this because it can sometimes signal that enrollment or the study itself is running slower than planned, but a date change can also come from routine scheduling, and the company hasn't said why it moved. On its own, this change doesn't prove that anything is wrong with the study.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
AMGNStudy Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab12Calm
Pushed back the final finish date by about 18 months: Sep 30, 2028 → Apr 2, 2030.
Amgen's late-stage study (Phase 3, a test of whether a treatment works in a larger group of patients) has pushed its final finish date from 2028-09-30 to 2030-04-02, about 18 months later, and it is no longer signing up new patients. A later finish date can be a worry for investors because it may mean the study is moving more slowly than planned, which could point to problems with the trial itself. But delays also happen for ordinary reasons, such as scheduling or paperwork, and the company hasn't said why this one moved, so the change alone doesn't prove anything.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
AMGNStudy Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab12Calm
Pushed back the main results date by about 33 months: Jul 5, 2027 → Apr 2, 2030.
Amgen pushed back the expected date for the main results of a late-stage study of its lung cancer drug tarlatamab, from July 2027 to April 2030, which is about 33 months later. Investors often watch changes like this because a delayed result can signal that a trial is taking longer than planned, which may point to slower progress or problems with the study. The change is an ordinary one, though, and companies move these dates for many reasons, so by itself it doesn't show that anything is wrong with the drug or the trial. The company hasn't said why the date moved.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
GLUEStudy of Oral MRT-2359 in Selected Cancer Patients13Calm
Pushed back the main results date by about 7 months: May 2026 → Dec 2026.
The company is Monte Rosa Therapeutics, which trades as GLUE, and it is testing an oral cancer drug called MRT-2359 in a Phase 1/2 trial (an early-stage study that checks safety and looks for signs the drug works). The trial has stopped signing up new patients but is still running, and the date for its main results has moved from May 2026 to December 2026, about 7 months later. Investors watch for this kind of change because a delayed results date can hint that the study is taking longer than planned, which might point to slower enrollment, extra follow-up, or problems in the data. Still, a date moving is also common for ordinary reasons, such as scheduling changes or a decision to collect more information, so by itself it doesn't show that anything is wrong with the drug or the study.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026

Hiding routine edits like “started signing up patients” and small date tweaks.